Cancer drug developer Evaxion Biotech's FY25 net loss narrows on higher revenue

Overview

• Denmark TechBio firm's 2025 net loss narrows to $7.7 mln, driven by higher revenue and lower operating expenses

• 2025 revenue of $7.5 mln from MSD option fee and Gates Foundation grant

• Company's cash position strengthened with over $30 mln in new capital

Outlook

• Company expects operational cash burn of ~$14 mln in 2026

Result Drivers

• LICENSING DEAL - Licensing of EVX-B3 to MSD provided revenue and future income potential

• EXPENSES - Research and development (R&D) expenses were $10.0 million for the year 2025.

Company press release: ID:nGNXbpCYJF

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Evaxion A/S is $10.50, about 237.6% above its March 4 closing price of $3.11

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.